Diabetes Therapies from Adipose Derived Stem Cells

脂肪干细胞的糖尿病治疗

基本信息

批准号：
7992863
负责人：
YOLANDA Renee LEA-CURRIE
金额：
$ 36.32万
依托单位：
ZEN-BIO, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7992863
关键词：
Acute Adipocytes Adipose tissue Affect Amino Acids Applications Grants Autologous Transplantation Biology Biopsy Blood Glucose Bone Marrow Cell Culture Techniques Cell Fraction Cell Lineage Cell Therapy Cell surface Cells Clinical Research Collection Data Diabetes Mellitus Disease Disease Progression Endothelial Cells Environment Etiology Excision of redundant skin of eyelid Fatty acid glycerol esters Glucagon Glucose Goals Hormones Human Incidence Insulin Life Mesenchymal Metabolic Control Nature Non-Insulin-Dependent Diabetes Mellitus Obesity Operative Surgical Procedures Pancreas Pancreatic Polypeptide Pharmaceutical Preparations Phase Population Prevalence Procedures Process Production Protocols documentation Recording of previous events Research Serum Small Business Innovation Research Grant Somatostatin Source Staging Stem cells Structure of beta Cell of islet Suction Lipectomy Surgeon Techniques Therapeutic Tissues Work adult stem cell bariatric surgery blood glucose regulation cell type diabetes mellitus therapy diabetic drug development experience ghrelin glucagon-like peptide 1 glycemic control insulin secretagogues insulin secretion islet mortality new technology prevent public health relevance research study response stem cell population type I and type II diabetes

项目摘要

DESCRIPTION (provided by applicant): Diabetes affects the lives of hundreds of millions of people worldwide and the incidence rate is continuing to rise. About 8% of the US population is estimated to have Type 1 or Type 2 diabetes, with the prevalence of Type 2 diabetes increasing with the rise in obesity. Even though the etiology of Type 1 and Type 2 diabetes is different, the end stages show a similar reduction or loss of pancreatic insulin secretion. This is caused by destruction of the pancreatic beta cells which produce and secrete insulin in response to serum glucose levels. Current diabetes therapies do not offer the degree of metabolic control needed to prevent the progression of the disease to the serious complications and mortality that occur when glucose control is lost. The potential for excellent, long-term glycemic control offered by a "beta-like", insulin producing cell is the rationale for our proposal. This cell would release insulin in a physiologically controlled, glucose-dependent manner, responding minute-to-minute to acute changes in blood glucose levels. In this situation, diabetes would be completely controlled. We have obtained significant preliminary data suggesting that adipose-derived stem cells can be differentiated in culture to "beta-like" insulin producing cells, and propose to develop applications of these cells for use in cell therapy and drug development. It is our goal to identify and characterize an optimized adult stem cell population from human adipose tissue that has the therapeutic potential for the treatment of diabetes. PUBLIC HEALTH RELEVANCE: Current diabetes therapies do not offer the degree of metabolic control needed to prevent the progression of the disease to the serious complications and mortality that occur when glucose control is lost. Our objective is to identify and characterize an adult stem cell population from human adipose tissue that has the therapeutic potential to differentiate into insulin-secreting pancreatic "beta-like" cells. If successful, this work would offer the possibility for cell treatment and possible cure of type 1 and type 2 diabetes.

描述（由申请人提供）：糖尿病影响着全世界数亿人的生活，且发病率持续上升。据估计，大约 8% 的美国人口患有 1 型或 2 型糖尿病，其中 2 型糖尿病的患病率随着肥胖人数的增加而增加。尽管 1 型和 2 型糖尿病的病因不同，但最终阶段显示出相似的胰腺胰岛素分泌减少或丧失。这是由于胰腺β细胞被破坏引起的，而胰腺β细胞会根据血糖水平产生和分泌胰岛素。目前的糖尿病疗法无法提供足够程度的代谢控制来防止疾病进展为严重并发症和死亡（当血糖失控时会发生这种情况）。 “类β”胰岛素产生细胞具有卓越、长期血糖控制的潜力，这是我们提议的理由。这种细胞会以生理控制的、葡萄糖依赖性的方式释放胰岛素，对血糖水平的急剧变化做出每分钟的反应。在这种情况下，糖尿病就会得到完全控制。我们已经获得重要的初步数据，表明脂肪干细胞可以在培养物中分化为“β样”胰岛素产生细胞，并建议开发这些细胞在细胞治疗和药物开发中的应用。我们的目标是从人类脂肪组织中鉴定和鉴定具有治疗糖尿病潜力的优化成体干细胞群。公众健康相关性：当前的糖尿病疗法无法提供足够程度的代谢控制来防止疾病进展为血糖失控时出现的严重并发症和死亡。我们的目标是鉴定和表征来自人类脂肪组织的成体干细胞群，该干细胞群具有分化为分泌胰岛素的胰腺“β样”细胞的治疗潜力。如果成功，这项工作将为细胞治疗和治愈 1 型和 2 型糖尿病提供可能性。